Brenda Maloney Shafer, Richard Davis and David Blank’s Article Showcased in Pratt’s Government Contracting Law Report

Many drug manufacturers have decided that the Health Resources and Services Administration’s Office of Pharmacy Affairs guidance on contract pharmacy encounters are causing significant disruption in operations and generating a loss of revenue for all types of 340B covered entities. In this issue of Pratt’s Government Contracting Law Report, Brenda Maloney Shafer, Richard Davis and David Blank elaborate on this problem and discuss how it is required for manufacturers to offer 340B pricing on appropriate drugs dispensed by contract pharmacies.

Resources